Hypoactive Sexual Desire Disorder (HSDD) Treatment Market 2019-2027 – Credence Research | Industry Size, Share & Forecast

Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Is Expected To Expand At A CAGR of 5.2%

SAN JOSE, United States - August 14, 2019 /MarketersMedia/ —

The latest market report published by Credence Research, Inc. “Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market - Growth, Future Prospects, Competitive Analysis, 2019- 2027,” the global hypoactive sexual desire disorder (HSDD) treatment market is set to expand at a CAGR of 5.2% from 2019 to 2027.

Browse the full report Hypoactive Sexual Desire Disorder (HSDD) Treatment Market - Growth, Future Prospects, Competitive Analysis 2019 – 2027 at https://www.credenceresearch.com/report/hypoactive-sexual-desire-disorder-hsdd-treatment-market

Market Insights

Hypoactive sexual desire disorder (HSDD) is currently on a rise in adult women population manifested by low self confidence and less connected with their partners. Recent approval of Vyleesi will provide essential momentum for the HSDD market growth. Currently 2 drugs such as BP101 and Prasterone 6.5 mg vaginal insert are under phase 3 clinical trial are being investigated for its safety and efficacy for treatment of HSDD.

Hypoactive sexual desire disorder is the most common type of sexual dysfunction occurring in adult women worldwide manifested by lack of sex interest for a period of six months or more due to personal distress or fluctuating sex hormones during the menstrual cycle. Accurate diagnosis of the symptoms manifested in hypoactive sexual desire disorder (HSDD) is very critical to finalize the treatment regimen which is either psychotherapy or pharmacotherapy. The PLISSIT model (Permission, Limited Information, Specific Suggestions and Intensive Therapy) aids in initial screening of HSDD. Psychotherapy is suggested to patients showing positive response to counseling sessions with sex therapist.

Request Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Research Sample: https://www.credenceresearch.com/sample-request/59843

Pharmacotherapy comprises of buspirone and bupropion off label treatment for HSDD in women suffering with low libido associated with anxiety and depression. Testosterone transdermal patches are used as an off label treatment in premenopausal and postmenopausal women with HSDD. Flibanserin is currently the only drug approved by USFDA for treating HSDD in premenopausal women owing to its multifunctional serotonin agonist and antagonist pharmacodynamic profile.

North America is the largest regional segment in the hypoactive sexual desire disorder (HSDD) treatment market representing a market share of 38.5%. The chief attributing factors responsible for its supreme market growth are growing incidence of low libido in the female population owing to increasing stress in daily life and fluctuating sex hormones during the menstrual cycle. Domicile of key players such as AMAG Pharmaceutcials, Allergan, Plc., S1 Biopharma, Inc. and Sprout Pharmaceuticals, Inc. further propel the market growth in North America regional segment. Europe is placed in the second position with a market share of 32.4% primarily due to affordable reimbursement scenario for the medicines prescribed for the treatment of hypoactive sexual desire disorder (HSDD). Asia Pacific holding a market share of 15.2% will be growing at a rapid pace during the forecast period owing to rising prevalence of HSDD in working women population and developing healthcare infrastructure.

Pharmaceutical companies providing pharmacotherapy for treating hypoactive sexual desire disorder are AMAG Pharmaceutcials, Allergan, Plc., Ivix, LLX., EndoCeutics, Inc., Emotional Brain BV., S1 Biopharma, Inc. and Sprout Pharmaceutcials, Inc.

Key Market Movements:

Growing incidence of low sex drive in women population worldwide
Affordable reimbursement scenario for pharmacotherapy employed in the treatment of HSDD
Recent approval of Vyleesi and strong product pipeline will further propel the HSDD market growth during the forecast period

Request Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Research Sample: https://www.credenceresearch.com/sample-request/59843

TOC:

1. Preface...

2. Executive Summary...

3. Hypoactive Sexual Desire Disorder Treatment Market: Dynamics and Future Outlook...

Chapter 4. Global Hypoactive Sexual Desire Disorder Treatment Market, by Therapy
4.1. Overview
4.2. Buspirone
4.3. Bupropion
4.4. Testosterone
4.5. Flibanserin
4.6. Bremelanotide
4.7. Cognitive Behavior Therapy
4.8. Pipeline Analysis
4.8.1. Phase III Drug
4.8.1.1. Prasterone 6.5 mg Vaginal Insert
4.8.1.2. BP101

Chapter 5. Global Hypoactive Sexual Desire Disorder Treatment Market, by Geography
5.1. Overview
5.2. North America Hypoactive Sexual Desire Disorder Treatment Market Analysis, 2017 – 2027
5.2.1. North America Hypoactive Sexual Desire Disorder Treatment Market, by Therapy, 2017 – 2027 (US$ Mn)
5.2.2. North America Hypoactive Sexual Desire Disorder Treatment Market, by Country, 2017 – 2027 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Hypoactive Sexual Desire Disorder Treatment Market Analysis, 2017– 2027
5.3.1. Europe Hypoactive Sexual Desire Disorder Treatment Market, by Therapy, 2017 – 2027 (US$ Mn)
5.3.2. Europe Hypoactive Sexual Desire Disorder Treatment Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Hypoactive Sexual Desire Disorder Treatment Market Analysis, 2017 – 2027
5.4.1. Asia Pacific Hypoactive Sexual Desire Disorder Treatment Market, by Therapy, 2017 – 2027 (US$ Mn)
5.4.2. Asia Pacific Hypoactive Sexual Desire Disorder Treatment Market, by Country/Region, 2017 – 2027 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific...

Chapter 6. Company Profiles
6.1. AMAG Pharmaceuticals
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Allergan, Plc.
6.3. Ivix LLX
6.4. EndoCeutics, Inc.
6.5. Emotional Brain BV ...

Browse the full report Hypoactive Sexual Desire Disorder (HSDD) Treatment Market - Growth, Future Prospects, Competitive Analysis 2019 – 2027 at https://www.credenceresearch.com/report/hypoactive-sexual-desire-disorder-hsdd-treatment-market

About Us:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.

Contact Info:
Name: Chris Smith
Email: Send Email
Organization: Credence Research
Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US
Phone: +18003618290
Website: https://www.credenceresearch.com

Source URL: https://marketersmedia.com/hypoactive-sexual-desire-disorder-hsdd-treatment-market-2019-2027-credence-research-industry-size-share-forecast/88908175

Source: MarketersMedia

Release ID: 88908175

More News From Enter Hollywood

Pell's appeal pitted word of former choirboy against priest

Aug 23, 2019

CANBERRA, Australia — Cardinal George Pell's appeal against his convictions for child molestation was largely a question of who the jury should have believed, his accuser or a senior priest whose church role was likened to Pell's bodyguard. Pell's accuser was a 13-year-old choirboy when he alleged that he was abused by then-Melbourne Archbishop Pell at the city's St. Patrick's Cathedral in December 1996 and February 1997. Monsignor Charles Portelli was a master of ceremonies at the 11 a.m. Sunday Masses where the choir sang. A chorister in the 1990s, David Dearing, told police that Portelli, Pell's right-hand man, was...

Chinese pop stars publicly back Beijing on Hong Kong

Aug 23, 2019

HONG KONG — At least eight pop stars from mainland China and one each from Taiwan and Hong Kong are publicly stating their support for Beijing's one-China policy, eliciting a mixture of disappointment and understanding from fans. Many of the statements came after protesters opposed to Beijing's growing influence over semi-autonomous Hong Kong removed a Chinese flag and tossed it into Victoria Harbour earlier this month. Lay Zhang, Jackson Wang, Lai Kuan-lin and Victoria Song were among the K-pop singers who recently uploaded a Chinese flag and declared themselves as "one of 1.4 billion guardians of the Chinese flag" on...

The Latest: Concerts canceled over Hong Kong airport protest

Aug 23, 2019

HONG KONG — The Latest on Hong Kong protests (all times local): 7 p.m. At least three concerts by overseas performers have been canceled in Hong Kong as protesters forced the city's airport to suspend operations for a second day. K-pop star Kang Daniel and Scottish band CHVRCHES both announced Tuesday that they are calling off upcoming events. American singer-songwriter Alec Benjamin canceled an upcoming concert late Monday. Kang's management office said the cancellation of a fan meeting scheduled for Sunday was because of safety concerns related to the protests, while CHVRCHES blamed "unforeseen circumstances." The airport protests are the...

China bans movies, actors from prominent Taiwan film awards

Aug 23, 2019

BEIJING — China said Wednesday it was banning Chinese movies and actors from participating in Taiwan's Golden Horse Awards, one of the Asian film industry's most prestigious honors, as Beijing ramps up economic and political pressure on the island it claims as its own territory. The one-sentence announcement on the microblog of China Film News, a newspaper affiliated with government film regulator, gave no reason for the suspension, but it comes amid rising tensions over Taiwan's refusal to recognize being part of Chinese territory to eventually be brought under Beijing's rule. Even without the ban, Chinese artists might have found...

Li Peng, Chinese premier during Tiananmen crackdown, dies

Aug 23, 2019

BEIJING — Li Peng, a former hard-line Chinese premier best known for announcing martial law during the 1989 Tiananmen Square pro-democracy protests that ended with a bloody crackdown by troops, has died. He was 90. China's official Xinhua News Agency said Li died Monday of an unspecified illness. His death was not announced until Tuesday evening. Li, a keen political infighter, spent two decades at the pinnacle of power before retiring in 2002. He left behind a legacy of prolonged and broad-based economic growth coupled with authoritarian political controls. While broadly disliked by the public, he oversaw China's reemergence from...

Sign up now!